Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Humacyte, Inc. (HUMA) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-generated summaries to help interpret complex documents. As a commercial-stage biotechnology platform company listed on Nasdaq, Humacyte files current and periodic reports that describe its bioengineered tissue programs, regulatory status, and capital structure.
Investors researching HUMA SEC filings can review Form 8-K current reports detailing material events such as credit facilities, revenue interest purchase agreements and their amendments or termination, registered direct offerings of common stock and warrants, at-the-market sales agreements, and senior secured term loan arrangements. These filings often explain how proceeds are intended to support commercialization of Symvess in the vascular trauma indication, development of acellular tissue engineered vessel (ATEV™) product candidates, and general corporate purposes.
Humacyte’s filings also identify it as an emerging growth company and disclose the listing of its common stock under ticker HUMA and redeemable warrants under HUMAW on The Nasdaq Stock Market. Over time, investors can expect Forms 10-K and 10-Q to provide detailed information on the company’s biotechnology platform, the approved ATEV for extremity vascular trauma, late-stage clinical trials in hemodialysis access and peripheral artery disease, preclinical programs, risk factors, and financial results.
On Stock Titan, AI-powered tools highlight key elements within lengthy filings, helping users quickly locate sections on financing terms, covenants, regulatory designations such as RMAT and Fast Track, and disclosures related to Symvess and other ATEV programs. The platform also surfaces Form 4 insider transaction reports and other ownership-related filings when available, giving a fuller view of executive and major holder activity. Use this page to monitor Humacyte’s regulatory reporting history, understand the obligations underlying its debt and equity financings, and follow how the company describes its bioengineered tissue platform to regulators and shareholders.
Humacyte (HUMA) filed its Q3 2025 report, showing early commercialization of Symvess. Total Q3 revenue was $753 (in thousands), including $703 from product sales and $50 from contracts. Cost of goods sold was $260. Operating expenses declined year over year, with R&D at $17,273 and SG&A at $7,610. Loss from operations narrowed to $(24,390), and net loss improved to $(17,510), helped by gains in fair-value items.
Year to date, revenue reached $1,571, while the net loss was $(16,029). Cash and cash equivalents were $19,488 at September 30, 2025. The company amended its Revenue Interest Purchase Agreement and made a $50.0 million repayment using previously restricted cash, eliminating that restriction as of quarter-end. Management believes cash on hand and remaining capacity under its equity line are sufficient for at least twelve months from issuance.
The company began capitalizing Symvess inventory in early 2025, recording $18.4 million as of quarter-end. Availability remained under financing programs, with $47.5 million left on the equity line and $62.7 million under the ATM facility.
Humacyte, Inc. furnished an 8‑K announcing that it issued a press release with financial results for its fiscal third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company states the information under Item 2.02, including the exhibit, is furnished and not deemed “filed” under the Exchange Act.
Humacyte’s securities trade as HUMA (common stock) and HUMAW (warrants) on Nasdaq.
Humacyte, Inc. filed an 8-K reporting a material event that includes a Securities Purchase Agreement dated
Humacyte, Inc. reported a material event on an Form 8-K documenting Amendment No. 2 to a Revenue Interest Purchase Agreement executed on
The filing indicates the inclusion of the amendment as an exhibit and an Inline XBRL cover page file. No financial terms, changes to covenants, or quantitative impacts were disclosed in the provided text, so the filing primarily records the contractual amendment rather than operational results.
Brady W. Dougan, a director of Humacyte, Inc. (HUMA), reported sales of common stock executed by Ayabudge LLC, an entity he controls. Between 08/18/2025 and 08/20/2025 Ayabudge sold a total of 2,241,045 shares in multiple transactions at weighted average prices of $1.83, $1.63 and $1.58 per share (per-footnote ranges: $1.79–$1.92, $1.57–$1.76, $1.53–$1.69). After the reported transactions Ayabudge beneficially owned 0 shares. The filing shows Mr. Dougan retains indirect beneficial ownership of 243,851 shares through his spouse and 1,148,240 shares through The Niklason Living Trust.
Laura E. Niklason, President, CEO and Director of Humacyte, Inc. (HUMA), reported changes in beneficial ownership on Form 4 related to sales of common stock held indirectly by Ayabudge LLC, an entity controlled by Brady W. Dougan. The filing discloses three groups of sales: 549,360 shares on 08/18/2025 at a weighted average price of $1.83, 1,100,000 shares on 08/19/2025 at a weighted average price of $1.63, and 591,685 shares on 08/20/2025 at a weighted average price of $1.58. Following the reported transactions, Ayabudge LLC's indirect holdings of those shares were reduced to zero. The filing also shows direct ownership of 243,851 shares and indirect ownership of 1,148,240 shares held by The Niklason Living Trust. The explanatory notes state the sales were executed by Ayabudge LLC to allow Mr. Dougan to pay down leverage and to provide a mechanism for investors to acquire shares; Dr. Niklason did not directly sell any shares. The Form 4 is signed on behalf of Dr. Niklason by an attorney-in-fact.
Humacyte, Inc. (HUMA) Form 144 reports a proposed sale of 591,685 common shares valued at $936,653.92 to be sold approximately on 08/20/2025 through UBS Financial Services on NASDAQ. The filer states the shares were originally acquired on 08/26/2021 as an early-stage investor position converted to Humacyte shares upon the company’s SPAC transaction; the original block purchased was 18,930,004 shares and payment was in cash. The filing also discloses recent dispositions by AYABUDGE LLC of 549,360 shares on 08/18/2025 (gross proceeds $997,429) and 1,100,000 shares on 08/19/2025 (gross proceeds $1,790,244). The filer certifies no undisclosed material adverse information.
Humacyte, Inc. notice of proposed sale reports an intended sale of 1,100,000 common shares through UBS Financial Services on or about 08/19/2025 on NASDAQ, with an aggregate market value of $1,790,244.50. The filing shows the shares were originally acquired on 08/26/2021 as early-stage investor holdings converted to Humacyte shares when the company went public via a SPAC, and payment for the original acquisition was in cash. The filer also reported sales during the prior three months: 549,360 shares sold on 08/18/2025 for gross proceeds of $997,429. The filing includes the filers representation that no undisclosed material adverse information is known.
Form 144 notice for HUMA (Humacyte, Inc.) reporting a proposed sale of common stock. The filer plans to sell 549,360 shares through UBS Financial Services Inc. on or about 08/18/2025, with an aggregate market value of $1,002,928.10. The company has 158,372,173 shares outstanding. The securities were originally acquired on 08/26/2021 as an early-stage investment in AHAC and converted to Humacyte shares when the company went public via SPAC; the original acquired amount shown is 18,930,004 shares with payment listed as cash. No securities were reported sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Humacyte reported early commercial activity for Symvess and maintained meaningful liquidity while continuing R&D spending. Cash and cash equivalents were $38.0 million with restricted cash of $50.2 million, totaling $88.4 million of cash and restricted cash. Total assets were $138.8 million and stockholders' equity was $4.1 million. The company recognized product and contract revenue of $0.3 million in Q2 2025 and $0.8 million for the six months ended June 30, 2025, and capitalized $11.1 million of inventory related to Symvess.
Operating expenses remained high: R&D was $37.4 million for six months and the operating loss was $52.9 million for the same period. Net results for the six months show a $1.5 million net income driven largely by a $44.3 million favorable change in the fair value of a contingent earnout liability, while the three‑month period posted a $37.7 million net loss. Financing activity included a $46.7 million public offering (net) and ATM proceeds of $3.6 million in the first half of 2025. The company implemented workforce reductions and expects existing cash plus available equity commitments to fund operations for at least twelve months from these interim statements.